Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy

Trial Profile

A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Ilixadencel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILIAD
  • Sponsors Immunicum
  • Most Recent Events

    • 06 Nov 2019 According to an Immunicum media release, the company expects to provide additional updates on the study during the second quarter of 2020.
    • 01 Oct 2019 According to an Immunicum media release, the Company has received confirmation from the Dose Escalation Committee (DEC) that ilixadencel showed a favorable safety profile with no serious adverse events in combination with Keytruda and based on these data the trial will continue testing the next dosage level.
    • 20 Aug 2019 According to an Immunicum media release, this study is progressing as planned and expect to provide a first update on the study later this year. Once the Phase Ib portion of the trial is complete, the company will then expect to receive data on dose levels and treatment schedules for use in the Phase II portion of the trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top